A Research Study Comparing RYBELSUS® to Other Blood Sugar Lowering Tablets in People Living in America With Type 2 Diabetes (REALYSE)
← catalyst calendarSponsored by Novo Nordisk A/S (industry) · NVO — their whole pipeline →.
Phase
Phase 4
Status
Completed
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,018actual
Sites
25
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-09-01 | actual | When the study began enrolling |
| Primary completion | 2025-06-18 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-06-18 | actual | The whole study's end, after follow-up |
| First posted | 2021-09-05 | actual | When this record first appeared on the registry |
| Results posted | 2026-08-10 | actual | When the sponsor posted results to the registry |
| Record updated | 2026-08-10 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Diabetes Mellitus, Type 2
Interventions
- Drug: semaglutide
- Drug: oral glucose-lowering medications (commercially available)
Primary outcome
what the primary-completion date above is the date OFChange in Glycated Haemoglobin (HbA1c)
measured Week 0, year 1
Posted documents
hosted by the registry — we link, never re-serveStudy Protocolposted 2025-02-18 · 946 KB · Prot_002.pdf
Statistical Analysis Planposted 2025-07-21 · 721 KB · SAP_003.pdf
Permalink · NVO's whole pipeline · Catalyst calendar · Every registered study · What changed